This study introduces a novel approach involving the formulation of controlled-release ketorolac gels, which have demonstrated efficacy when administered topically. The investigation delves into the potential of these gels as carriers for the delivery of ketorolac. The release pattern of the drug in vitro, across all formulations, followed a diffusion-controlled mechanism characterized by a zero-order pattern. Furthermore, these formulations displayed compatibility with skin application and stability congruent with ICH guidelines. The optimized ketorolac gel stood out with a substantial reduction in paw edema, achieving a noteworthy 77.02% reduction after 6 hours. Nonetheless, it was observed that the optimized gel did not exert a significant effect on the inhibition of 5-lipoxygenase, even at higher doses. Based on these findings, the ketorolac gel comprising 0.5 g of Carbopol emerged as the optimized formulation for addressing localized inflammation.